Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 15;13(6):1087–1095. doi: 10.1111/cts.12880

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Possible mechanism of anti‐inflammatory effects of low molecular weight heparin (LMWH) in patients with coronavirus disease 2019 (COVID‐19). Under conventional antiviral treatment regimens, LMWH improves hypercoagulability, inhibits IL‐6 release, and attenuates IL‐6 biological activity. It has potential antiviral effects and helps delay or block inflammatory cytokine storms. LMWH can increases the lymphocyte% in the patients. The multiple effects of LMWH encourages its application for the treatment of patients with COVID‐19. HSPG, heparin sulfate proteoglycan; SARS‐CoV‐2, severe acute respiratory syndrome‐coronavirus 2.